HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuva... von Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Ahn, Jin-Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Kim, Sung-Bae, Lichinitser, Mikhail, Starosławska, Elżbieta, Kunz, Georg, Falcon, Silvia, Chen, Shou-Tung, Crepelle-Fléchais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier

Volltext

Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-... von Lindeman, Geoffrey J., Fernando, Tharu M., Bowen, Rebecca, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Fléchais, Aulde, Wilson, Timothy R., Bardia, Aditya

Volltext

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results von Lindeman, Geoffrey J, Fernando, Tharu M, Bowen, Rebecca, Jerzak, Katarzyna J, Song, Xinni, Decker, Thomas, Boyle, Frances, McCune, Steve, Armstrong, Anne, Shannon, Catherine, Bertelli, Gianfilippo, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Wilson, Timothy R, Flechais, Aulde, Bardia, Aditya

Volltext

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA -m... von Juric, Dejan, Kalinsky, Kevin, Im, Seock-Ah, Ciruelos, Eva M, Bianchini, Giampaolo, Barrios, Carlos H., Jacot, William, Schmid, Peter, Loi, Sherene, Rugo, Hope S., Craine, Veronica, Hutchinson, Katherine E., Flechais, Aulde, Thanopoulou, Eirini, Harbeck, Nadia

Volltext

Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progressi... von Lindeman, Geoffrey J, Bardia, Aditya, Bowen, Rebecca, Flechais, Aulde, Lei, Guiyuan, Hogea, Alexandra, Mobasher, Mehrdad, Rafii, Saeed

Volltext

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, local... von Lindeman, Geoffrey J, Bowen, Rebecca, Jerzak, Katarzyna Joanna, Song, Xinni, Decker, Thomas, Boyle, Frances M., McCune, Steven L., Armstrong, Anne, Shannon, Catherine M., Bertelli, Gianfilippo, Fernando, Tharu M, Desai, Rupal, Gupta, Kushagra, Hsu, Jerry Y., Flechais, Aulde, Bardia, Aditya

Volltext

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC) von Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Crepelle-Flechais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier B.

Volltext